Ameriprise
ANIX icon

Ameriprise’s Anixa Biosciences ANIX Stock Holding History

Ameriprise’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,400
Closed -$34K – 3887
2022
Q1 		$34K Hold
12,400
– – ﹤0.01% 3886
2021
Q4 		$37K Sell
12,400
-2,300
-16% -$9.3K ﹤0.01% 3915
2021
Q3 		$70K Buy
14,700
+4,300
+41% +$19.4K ﹤0.01% 3803
2021
Q2 		$40K Buy
+10,400
New +$44.3K ﹤0.01% 3857

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ameriprise's ANIX Position: Q2 2022 in Review

Ameriprise sold out of Anixa Biosciences (ANIX) in Q2 2022, closing a stake of 12,400 shares — an estimated $34K sold.

Ameriprise first reported a position in ANIX in Q2 2021 and held it in 4 quarters. The position peaked at $70K in Q3 2021. 45 funds tracked by Wall St. Rank hold ANIX as of Q2 2022.

  • Ameriprise reported no remaining Anixa Biosciences position as of Q2 2022 after selling out during the quarter.
  • Ameriprise sold 12,400 Anixa Biosciences shares in Q2 2022, an estimated $34K.
  • Ameriprise first reported a position in Anixa Biosciences in Q2 2021 and held it in 4 quarters.
  • Ameriprise's Anixa Biosciences position peaked at $70K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2022.

Based on Ameriprise's 13F filing for Q2 2022, filed 15 Aug 2022.